Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.
Welcome to NeurologyLive
's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive
's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Stroke Care Evolves During These Uncertain Times
Andrew Russman, DO, medical director, Comprehensive Stroke Center, Cleveland Clinic, and guest editor for NeurologyLive
, provides insight on how stroke care has changed during the COVID-19 pandemic.
2: Severe COVID-19 in Multiple Sclerosis Linked to Disability Status, Age, Obesity
Notably, the cohort assessment did not identify a link between exposure to disease-modifying therapies and COVID-19 severity, while EDSS was associated with the highest variability of COVID-19 severe outcome, followed by age and obesity.
3: Long-Term Data for Cannabidiol in Dravet Syndrome
Anup Patel, MD, section chief, Pediatric Neurology, Nationwide Children's Hospital, shared insight on the open-label extension trial that analyzed long-term safety and efficacy with cannabidiol in patients with Dravet syndrome.
4: Telemedicine in Dementia Care: Here to Stay?
In part 2 of this interview, Jessica Zwerling, MD, MS, associate director of the Center for the Aging Brain at Montefiore Medical Center, anticipates life with telemedicine after the pandemic and describes the at-home advantage it gives clinicians.
5: Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS
Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2020 Meeting reviewing first-line ocrelizumab compared to glatiramer acetate and dimethyl fumarate for treatment of relapsing-remitting multiple sclerosis.